A 53-year-old woman came to the emergency department with three weeks of severe epigastric pain radiating to her back, intermittent vomiting, unintentional weight loss, and dark urine. She had a 30-pack-year smoking history. Imaging found a pancreatic mass, and her CA 19-9, a tumor marker heavily associated with pancreatic cancer, was significantly elevated.
Almost everything about the presentation pointed toward pancreatic ductal adenocarcinoma, a cancer usually caught too late for curative surgery. It was not cancer. Her IgG4 level was raised, and she responded to biliary decompression and corticosteroids, potentially avoiding extensive surgical intervention. On follow-up, both her CA 19-9 and IgG4 normalized.
Jaundice, a Mass, and a Tumor Marker Pointing the Wrong Way
Type 1 autoimmune pancreatitis is the pancreatic form of IgG4-related disease, a systemic fibroinflammatory condition that produces tumor-like swellings in whichever organ it targets. In the pancreas, it goes by the older name lymphoplasmacytic sclerosing pancreatitis, and it predominantly affects middle-aged and older adults.
The classic presentation is obstructive jaundice with weight loss, which is precisely how pancreatic head cancer announces itself. When it also narrows the bile duct inside the pancreas, the cholangiography looks the part too.
Even the blood work misleads. CA 19-9 rises in biliary obstruction from any cause, so an elevated result in a jaundiced patient with a pancreatic mass does not distinguish between the two diagnoses at all.
The disease is also not confined to the pancreas. IgG4-related disease can involve the bile ducts, salivary glands, kidneys, orbits, retroperitoneum, and aorta, and finding a second affected organ is one of the more useful clues that a pancreatic mass is inflammatory.
The Fingerprint That Separates Inflammation from Cancer
Several features do separate them, though none is decisive on its own.
Elevated serum IgG4 is the most useful single blood marker. On tissue, the diagnosis rests on a specific triad: dense infiltration by IgG4-positive plasma cells, storiform fibrosis with its distinctive whorled pattern, and obliterative phlebitis. International consensus diagnostic criteria established in 2011 pull clinical, radiological, histological and serological strands together, and separate type 1 disease from type 2, which is IgG4-negative and shows different histology.
Response to steroids is itself part of the diagnostic picture, which creates an uncomfortable circularity: a trial of treatment can confirm the diagnosis, but only if someone suspected it enough to try.
Imaging contributes its own clues. Type 1 disease classically produces diffuse enlargement of the pancreas with a rim of surrounding tissue, a pattern radiologists sometimes describe as sausage-shaped, alongside irregular narrowing of the main pancreatic duct. The trouble is that a focal mass in the head of the pancreas, as this patient and many others present, looks nothing like the textbook appearance.
The Patients Who Get an Operation They Did Not Need
Missing it carries a real price, because the surgery for pancreatic head cancer is a pancreaticoduodenectomy, or Whipple procedure, one of the most demanding operations in abdominal surgery.
That is what happened to one patient whose abdominal CT showed a nearly five-centimeter mass in the pancreatic head and whose CA 19-9 came back at 1,568 units per milliliter against an upper limit of 37. Suspicion of cancer was high enough that she underwent a pylorus-sparing Whipple. The histopathology was benign, showing the lymphoplasmacytic infiltrate, periductal fibrosis and phlebitis of autoimmune pancreatitis.
Other teams have pulled back from the brink. In another jaundice case with raised CA 19-9, clinicians reached the correct answer through ERCP and tissue biopsy and concluded that a thorough workup is what avoids unnecessary surgical intervention.
The genuine risk of overcorrection deserves to be stated plainly. Pancreatic cancer is far more common than autoimmune pancreatitis, and delaying surgery in a resectable tumor to trial steroids can be fatal. Cases also run the other way, with cancers initially treated as inflammation. The point is not that pancreatic masses are usually benign. It is that when the picture does not quite fit, IgG4 testing and tissue sampling are worth the days they cost.
A First Approved Drug Changes the Long Game
Until recently, steroids were essentially the whole treatment, which is a problem in a relapsing disease. Long-term glucocorticoid exposure brings bone loss, diabetes, infection risk, and weight gain.
That changed in April 2025, when the FDA approved inebilizumab-cdon, marketed as Uplizna, as the first treatment for IgG4-related disease in adults. The drug depletes CD19-positive B cells, and the approval rested on MITIGATE, the first randomized, double-blind, placebo-controlled trial ever conducted in the condition.
Among 135 randomized participants, 10.3% of those receiving inebilizumab had at least one flare within 52 weeks, against 59.7% on placebo, an 87% reduction in risk. Nearly six in ten reached flare-free, corticosteroid-free complete remission, compared with just over two in ten on placebo.
The trade-offs are real. Serious adverse events of grade 3 or higher occurred in 18% of the treatment group and 9% of the placebo group. The drug is contraindicated in patients with active hepatitis B or active or untreated latent tuberculosis. And it is expensive, with a wholesale acquisition cost of $140,248.50 per dose (three vials), given every six months after two loading doses. Anyone facing that decision needs a specialist who knows the disease.
Key Questions Answered
What is type 1 autoimmune pancreatitis?
The pancreatic manifestation of IgG4-related disease, a systemic inflammatory condition that produces tumor-like swellings in affected organs. It responds to corticosteroids, unlike pancreatic cancer.
Why is it confused with pancreatic cancer?
It produces a pancreatic mass, obstructive jaundice and weight loss, and can raise the tumor marker CA 19-9, which rises with biliary obstruction from any cause. Imaging alone often cannot separate them.
How do doctors tell them apart?
Elevated serum IgG4, characteristic histology showing IgG4-positive plasma cells, storiform fibrosis, and obliterative phlebitis, and response to steroids. International consensus criteria combine clinical, imaging, tissue, and blood findings.
What happens if it is misdiagnosed?
Patients can undergo a Whipple procedure, a major operation, for a condition that steroids would have treated. Published cases document exactly that outcome. The reverse error, treating cancer as inflammation, is also dangerous.
Is there a treatment beyond steroids?
Yes. In April 2025, the FDA approved inebilizumab-cdon for IgG4-related disease in adults, the first approved therapy. In its pivotal trial, 10.3% of treated patients experienced a flare within a year, compared with 59.7% on placebo.
Should someone with a pancreatic mass expect this diagnosis?
No. Pancreatic cancer is far more common, and delaying surgery for a resectable tumor is dangerous. Autoimmune pancreatitis belongs on the differential, not at the top of it.
